Vismodegib
|
|
|
- CAS-Nr.
- 879085-55-9
- Englisch Name:
- Vismodegib
- Synonyma:
- Vismodegib;GDC-0449;Erivedge;101098;CS-1913;RG 3616;Vimodji;VisModegib Base;Vismodegib 13C7;Vismodegib, >=99%
- CBNumber:
- CB52500590
- Summenformel:
- C19H14Cl2N2O3S
- Molgewicht:
- 421.3
- MOL-Datei:
- 879085-55-9.mol
|
Vismodegib Eigenschaften
- Schmelzpunkt:
- 179-181°C
- Siedepunkt:
- 561.6±50.0 °C(Predicted)
- Dichte
- 1.440
- storage temp.
- -20°
- L?slichkeit
- Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 10 mg/ml with warming)
- Aggregatzustand
- White solid.
- pka
- 10.72±0.70(Predicted)
- Farbe
- Off-white or beige
- Stabilit?t:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
- InChI
- InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
- InChIKey
- BPQMGSKTAYIVFO-UHFFFAOYSA-N
- SMILES
- C(NC1=CC=C(Cl)C(C2=NC=CC=C2)=C1)(=O)C1=CC=C(S(C)(=O)=O)C=C1Cl
Vismodegib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
In January 2012, the US FDA approved vismodegib (also referred to as
GDC-0449) for the treatment of adults with metastatic basal cell carcinoma
(BCC), with locally advanced BCC that has recurred following surgery or
who are not candidates for surgery or radiation. Vismodegib inhibits the Hh sig?naling pathway by functioning as an antagonist of SMO thereby inhibiting the activation of Hedgehog target genes, resulting in decreased downstream pro?duction of proliferation factors. The IC
50 of vismodegib in a Hedgehog?responsive cell line derived from human embryonic palatal mesenchyme cells was 2.8 nM. In preclinical in vivostudies, vismodegib at 12.5 mg/kg (bid) caused complete regression of tumors in a Hh pathway dependent medulloblas?tomaallograft model generated from Ptch+/-mice. A synthesis of vismodegib starting from 2-chloro-5-nitro aniline and employing a Negishi coupling with 2-pyridyl zinc iodide as a key step has been reported.
Chemische Eigenschaften
White Solid
Definition
ChEBI: A benzamide obtained by formal condensation between the carboxy group of 2-chloro-4-(methylsulfonyl)benzoic acid and the anilino group of 4-chloro-3-(pyridin-2-yl)aniline. Used for the treatment metastatic basal cell carcinoma.
Vismodegib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Vismodegib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 242)Lieferanten
- 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
- VisModegib (GDC-0449)
- BenzaMide, 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(Methylsulfonyl)-
- GDC-0449,Vismodegib
- 2-Chloro-N-(4-chloro-3-(pyridin-2-yl)-phenyl)-4-(methylsulfonyl)benzamide
- VisModegib Base
- 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide Vismodegib(GDC0449)
- Vismodegib 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide
- Vismodegib, >=99%
- VISMODEGIB (GDC-0449);GDC0449
- 101098
- CS-1913
- Vismodegib, 98%, a Hedgehog inhibitor
- GDC04499(Vismodegib)
- GDC-0449;GDC 0449;GDC0449
- RG 3616
- 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide USP/EP/BP
- 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfon...
- 2-Chloro-N-(4-chloro-3-(pyridine-2-yl)phenyl)-4-(methylsulfonyl)benzamide
- Vismodegib 13C7
- TIANFU-CHEM Vismodegib (GDC-0449)
- Erivedge
- GDC-0449
- Vismodegib
- 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-methanesulfonylbenzamide
- Vimodji
- Xanthophyll Impurity 3
- 879085-55-9
- Inhibitors
- Aromatics
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Inhibitor
- API
